These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 37482021)

  • 1. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
    Tan B; Joyce R; Tan H; Hu Y; Wang J
    Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease.
    Shen W; Chen X; Zhou L; Cheng Y; Zhang Y; Jiang X; Sun H; Shen J
    Bioorg Med Chem Lett; 2024 Nov; 112():129942. PubMed ID: 39218405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead.
    Dayan Elshan NGR; Wolff KC; Riva L; Woods AK; Grabovyi G; Wilson K; Pedroarena J; Ghorai S; Nazarian A; Weiss F; Liu Y; Mazumdar W; Song L; Okwor N; Malvin J; Bakowski MA; Beutler N; Kirkpatrick MG; Gebara-Lamb A; Huang E; Nguyen-Tran VTB; Chi V; Li S; Rogers TF; McNamara CW; Gupta AK; Rahimi A; Chen JJ; Joseph SB; Schultz PG; Chatterjee AK
    J Med Chem; 2024 Feb; 67(4):2369-2378. PubMed ID: 38335279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
    Bai B; Arutyunova E; Khan MB; Lu J; Joyce MA; Saffran HA; Shields JA; Kandadai AS; Belovodskiy A; Hena M; Vuong W; Lamer T; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    RSC Med Chem; 2021 Oct; 12(10):1722-1730. PubMed ID: 34778773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.
    Zhu M; Fu T; You M; Cao J; Yang H; Chen X; Zhang Q; Xu Y; Jiang X; Zhang L; Su H; Zhang Y; Shen J
    Bioorg Med Chem; 2023 May; 87():117316. PubMed ID: 37187077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.
    Uzuner U; Akkus E; Kocak A; Çelik Uzuner S
    J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
    J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and virologic mechanism of the emergence of resistance to M
    Hattori SI; Bulut H; Hayashi H; Kishimoto N; Takamune N; Hasegawa K; Furusawa Y; Yamayoshi S; Murayama K; Tamamura H; Li M; Wlodawer A; Kawaoka Y; Misumi S; Mitsuya H
    Proc Natl Acad Sci U S A; 2024 Sep; 121(37):e2404175121. PubMed ID: 39236245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
    Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
    Pillaiyar T; Flury P; Krüger N; Su H; Schäkel L; Barbosa Da Silva E; Eppler O; Kronenberger T; Nie T; Luedtke S; Rocha C; Sylvester K; Petry MRI; McKerrow JH; Poso A; Pöhlmann S; Gütschow M; O'Donoghue AJ; Xu Y; Müller CE; Laufer SA
    J Med Chem; 2022 Jul; 65(13):9376-9395. PubMed ID: 35709506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
    Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
    Kneller DW; Li H; Phillips G; Weiss KL; Zhang Q; Arnould MA; Jonsson CB; Surendranathan S; Parvathareddy J; Blakeley MP; Coates L; Louis JM; Bonnesen PV; Kovalevsky A
    Nat Commun; 2022 Apr; 13(1):2268. PubMed ID: 35477935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.